PSMA-targeted monoclonal antibody conjugated with microtubule disrupting agent monomethyl auristatin E (MMAE) targets PSMA, transmembrane peptidase upregulated on endothelial GBM cells. This evidence concerns the gene FOLH1 and glioblastoma.